SETD2 and cancer: SETD2 alterations, as well as autophagy deficiencies, have been associated with several pathophysiologies, including neurodevelopmental disorders, Luscan-Lumish syndrome and several cancer types such as renal cell carcinoma, breast cancer or leukemia [25, 26, 50–52].